The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies
June 27, 1999
Garcia and colleagues investigated plasma lipid levels and lipodystrophy incidence in patients with early HIV disease who had received one year of a dual or triple antiretroviral regimen. Patients were randomized to one of the following treatment arms:Abstract: Incidence of Metabolic Changes and Lipodystrophy in Two Trials Comparing Double Versus Triple Antiretroviral Therapy in Early HIV Disease
Only the d4T + 3TC + ritonavir (RTV) treatment arm showed changes in laboratory parameters, with increases in cholesterol and triglycerides. One patient in the group had a cholesterol level above normal, while the percentage of patients with abnormal triglycerides increased from 23% at baseline to 62% at follow up. Lipodystrophy was uncommon in the study; it was observed in only one patient receiving dual therapy and one patient receiving triple therapy.
The data suggest that disease state or length of infection may be associated with clinical lipodystrophy. It also indicates that RTV use may be involved in the elevation of triglycerides and cholesterol.
Authored by: F. Garcia, M. Ortega, A. Cruceta, C. Tortajada, A. Soriano, L. Zamora, J.M. Miro, T. Pumarola and J.M. Gatell for the Spanish EARTH Studies
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.